XCUR · Exicure, Inc.
$1.00
-0.03 (-3.04%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management believes that, given the Company's current cash position, operating plans and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. Additional financing will be needed to fund ongoing operations, support of GPCR USA's operations, and exploration of strategic alternatives and pursuing any alternatives that management identifies. Management's plan to alleviate this substantial doubt include pursuing additional equity and/or debt financings, strategic transactions, potential business combination opportunities and other sources of capital. However, there can be no assurance that such plans will be successful.”View the 10-Q filed Aug 14, 2026
Market Cap
$7.14M
Shares
6.55M
Volume · Oct 20
43.75K
Avg daily vol (3M)
41.72K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.00
Open$1.11
Day$0.99–1.11
52W close$1.00–7.29
Avg vol 30d37K
Short int38K · 0.6% float · 2.0d
Short vol5%
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$8.28M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.72M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.9%
Year over year · more shares
Price change (1Y)
-77.3%
Trailing year
Short interest
0.6%
Latest settlement · 2.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−66%
below
Price vs 50-day avg
−19%
below
RSI (14)
37
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−23%
trailing
6-month return
−70%
trailing
YTD return
−82%
this year
Relative strength
−78%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.57% of float · ▼ -46.9% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
17 holders — mid 3-yr range
Squeeze score
38
low risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+83%
Y/Y
Free cash flow
$-8.6M
Balance sheet
$27.8M
net cash
Quant / Vol
risk profile
Volatility
108%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
11.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−66%
Bearish
Price vs 50-day avg
−19%
Bearish
RSI (14)
37
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.57% of float · ▼ -46.9% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
17 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $7
vs 200-day avg -66%
vs 50-day avg -19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Full time employees | 2 | the three months ended March 31, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XCUR
this stock
Exicure, Inc.
|
$7.14M | -81.6% | -100.0% | — | 0.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XCUR | -13.2% | -22.6% | -69.8% | -16.1% | -81.6% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -12.0% | -22.0% | -77.9% | -16.9% | -94.4% |